U.S. Food and Drug Administration Approves BARACLUDE[R] (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease.

Extract

---

U.S. Food and Drug Administration Approves BARACLUDE[R] (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease.

Viral load reduction at 48 weeks in difficult-to-treat chronic hepatitis B patient population

At 48 weeks, 57 percent (57/100) of patients treated with BARACLUDE ( )achieved an undetectable viral load compared to 20 percent (18/91) of patients who received adefovir (1 )

PRINCETON, N.J. -- Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease. BARACLUDE is indicated for the treatmen...

See the full content of this document

---